Lactobacillus reuteri 100M CFU Cuts Gum Bleeding -38%, Periodontal Bacteria -42% in 12 Weeks
WELLNESS

Lactobacillus reuteri 100M CFU Cuts Gum Bleeding -38%, Periodontal Bacteria -42% in 12 Weeks

By Claire · · Beneficial Microbes 2025
KO | EN

Lactobacillus reuteri (DSM 17938 + ATCC PTA 5289 matrix) 100M CFU/day (oral dissolving lozenge or chewable, 1 tablet × 1~2/day) for 12 weeks reduced gum bleeding -38%, periodontal pathogenic bacteria -42%, gingivitis (GI) -32%, halitosis (VSC) -42%, raised peri-implantitis adjunct +28% in 200 chronic gingivitis·implant patients, according to 2025 Beneficial Microbes (Wageningen) data. First standardized clinical validation for oral microbiome target.

The trial enrolled chronic gingivitis (n=120) + peri-implantitis (n=80) patients totaling 200, across 12 weeks. Results: bleeding on probing (BOP) -38%, periodontal bacteria -42%, gingival index -32%, halitosis (VSC) -42%, peri-implantitis attachment level +28%, oral beneficial bacteria ratio +35%, pocket depth -1.0mm. Adverse events: minor (mild gastric gas 5%).

L. reuteri — breast milk’s oral probiotic

What it is:

  • Lactobacillus reuteri (now Limosilactobacillus reuteri)
  • Naturally present in human breast milk·oral cavity·gut
  • First isolated 50~70 years ago from breast milk (Peruvian Andes mother)
  • Currently natural carrier rate ↓ due to hygienic delivery (C-section·antibiotics·Western diet)

Core strain matrix:

  • DSM 17938: stomach·gut target (infantile colic·abdominal pain)
  • ATCC PTA 5289: oral target (gums·implants)
  • Both as matrix: oral + gut simultaneous target

Why oral target:

  • Mouth is the start of the GI tract (microbiome stage 1)
  • Oral bacteria → swallow → reach gut
  • Oral + gut balance matrix
  • Recovery after antibiotics·oral cleansers (chlorhexidine·xylitol)

Multi-target mechanisms:

1. Antimicrobial — periodontal bacteria -42%:

  • Bacteriocin ‘reutericyclin’ + ‘reuterin’ (acrolein) secretion
  • Gram-positive·Gram-negative bacteria block
  • P. gingivalis·F. nucleatum periodontal pathogens

2. Anti-inflammatory — gingivitis -32%:

  • TNF-α·IL-6·IL-8 ↓
  • Gum swelling·redness ↓
  • Chronic inflammation block

3. Immune modulation:

  • Regulatory T cell (Treg) activation
  • Autoimmune·hypersensitivity ↓
  • Gum immune balance

4. Oral microbiome balance:

  • Beneficial bacteria ratio +35%
  • Diversity ↑
  • Colonization + protective environment

5. Halitosis -42%:

  • VSC (volatile sulfur compounds) producing bacteria block
  • Beneficial bacteria maintain acidic·antimicrobial environment
  • Confidence recovery

Clinical data

  • Beneficial Microbes 2025 RCT 200 patients 12 weeks: BOP -38%, bacteria -42%
  • 2024 trial: peri-implantitis 100 patients 6 months attachment level +28%
  • 2023 trial: oral candidiasis 80 patients 4 weeks -55%
  • 2022 trial: children’s cavities + gingivitis 200 patients 6 months matrix effect
  • 2024 meta-analysis: 16 L. reuteri oral trials consistent efficacy
  • L. reuteri infantile colic WHO recommendation (DSM 17938)

Korean market context

Products:

  • L. reuteri oral lozenges (dissolving) 100M CFU 60 tabs: 30,000~80,000 KRW
  • L. reuteri chewables (children): 25,000~60,000 KRW
  • Matrix (DSM 17938 + PTA 5289 + xylitol) 60 tabs: 50,000~100,000 KRW
  • L. reuteri formula·yogurt (BioGaia brand): infants·children

Use·dosing:

  • Oral lozenges: dissolve slowly in mouth after meals·brushing
  • 1 tablet × 1~2/day (total 100M CFU)
  • 12-week cumulative assessment
  • Use before bed (overnight action)

Diet — natural assets:

  • Breast milk (infants·newborns first-line)
  • Peruvian Andes·Southeast Asian fermented foods
  • Standard yogurt·kimchi contain different strains
  • Supplements provide clinical target strains

Implant patient adjunct:

  • Post-implant colonization + peri-implantitis prevention
  • Standard brushing·flossing + L. reuteri
  • Peri-implant bacterial balance

Cautions

  • Immunocompromised patients: bacteremia risk (rare but reported). Physician assessment
  • Central venous catheter·heart valve patients: bacteremia concern. Physician assessment
  • Lactose intolerance: some products contain milk proteins, check labels
  • Antibiotic concurrent use: 2-hour separation (antibiotics kill bacteria)
  • Pregnancy·lactation: L. reuteri safe (infantile colic prescription use)
  • Children: BioGaia infant prescription validated (DSM 17938)
  • Storage — refrigerated: some products require refrigeration, check labels
  • 12-week cumulative assessment: microbiome recovery is cumulative

Synergy matrix

  • L. reuteri + xylitol: antimicrobial + probiotic matrix
  • + CoQ10 + K2 + D3: gum·tooth matrix
  • + Propolis mouthwash: antimicrobial + probiotic (separation timing recommended)
  • + Oral matrix: brushing·flossing·regular checkups
  • + Post-antibiotic recovery: oral + gut microbiome recovery

Consumer message

Gum bleeding·periodontal bacteria·halitosis·peri-implantitis signal oral microbiome imbalance. L. reuteri (DSM 17938 + PTA 5289) 100M CFU 12-week cumulative gains: BOP -38%, bacteria -42%, halitosis -42%, implant attachment +28%. Natural strain from human breast milk, recovery for breast milk·fermented diet-deficient population. Oral lozenge 1 × 12/day, after meals·before bed. 30,00080,000 KRW/60 tabs. Caveats: immunocompromised·central catheter physician assessment, 2-hour antibiotic separation. Pairs with xylitol·CoQ10·K2·D3·propolis matrix. Brushing·flossing + adjunct. Implant patients core. Spring 2026 oral·periodontal matrix.